-transparent.png){kind=logo}
In the current study a technique for microencapsulation of human breast adenocarcinoma cells MCF-7 in alginate-chitosan microcapsules is used. Microencapsulation is proposed to generate multicellular tumor spheroids (MTS) based on these cells and to test them further as an in vitro model for anti-tumor drug screening. Cytotoxicity of methotrexate (MTX) was studied on the obtained MTS. A set of MTS with mean size of 150, 200 and 300 m was prepared in function of a cultivation time. After incubation of MTS in cultivation medium containing MTX at concentrations of 1, 2, 10, 50 and 100 nM for 48 hs cell viability was evaluated. MTS were shown to be more resistant to MTX than the monolayer culture, and the resistance to MTX was increased with enhancing a spheroid size. At MTX concentration of 100 nM a number of viable cells in MTS with the size of 300 m was 2.5-fold bigger than that one in monolayer culture. It is suggested that the cells in microencapsulated MTS can better mimic cell behavior in a small size solid tumor than the cells in a monolayer culture. In future microencapsulated MTS can be proposed as a novel in vitro model for anticancer drug screening.
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
July 2015,
Journal of nanoscience and nanotechnology,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
September 1998,
Cancer letters,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
February 1980,
Lijecnicki vjesnik,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
March 2012,
Biomaterials,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
June 2016,
International journal of oncology,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
January 2022,
American journal of cancer research,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
June 2016,
International journal of pharmaceutics,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
January 2016,
Biotechnology journal,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
October 2019,
Journal of clinical medicine,
A M Tsoĭ, and
D S Zaĭtseva-Zotova, and
É F Édelveĭs, and
A Bartkowiak, and
J -L Goegen, and
E L Vodovozova, and
E A Markvicheva
March 2014,
Molecular therapy. Nucleic acids,
